NKGen Biotech, Inc. Common Stock

SANTA ANA, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the Company's lead investigational program, troculeucel, at the 4th Great Bay Cell and Gene Therapy Forum, taking place September 22-23, 2026, in Guangzhou, China.

SANTA ANA, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (OTC: NKGN) (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous and allogeneic natural killer (“NK”) cell therapeutics, today announced that NKGen Chairman and Chief Executive Officer Paul Y. Song, M.D., will present on the potential of troculeucel, the Company's lead investigational program, for the treatment of neurodegenerative diseases at Biologics Manufacturing Korea 2026, taking place September 17-18, 2026, in Incheon, South Korea.